Clinical research on the optimum dosage of 1.ALPHA.(OH)D3(1.ALPHA.D3) for preventing secondary hyperparathyroidism (2.DEG.HPT).

DOI

Bibliographic Information

Other Title
  • 二次性副甲状腺機能こう進症（２°ＨＰＴ）の発症予防に関する１α（ＯＨ）Ｄ３至適投与量の臨床的検討

Description

Recently we have reduced the dosage of 1α D3 for hypercalcemia not only by changing the calcium concentration of dialysates ([D]Ca) but also by using CaCO3. In order to clarify the optimum dosage of 1αD3 for preventing 2°HPT, we performed a retrospective study as follows. Fifty maintenance hemodialysis patients were divided into several groups according to the conditions of administration of CaCO3 and 1α D3, and to [D]ca. In each group, the changes in calcium and bone metabolites were examined. The results showed that administration of 0.75-1.0μg/day of 1α D3 seemed to prevent an increase in serum C-PTH at normal serum Ca levels (mean 9.6mg/dl), but administration of a lower dosage (<0.5μg/day) was associated with a higher serum Ca level (mean 10.0mg/dl), and moreover, the serum P level tended to increase at the same time. Accordingly there is a danger of ectopic calcification. Therefore, we recommend the administration of 0.75-1.0μg/day 1α D3 as the optimum dosage for preventing 2°HPT.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390001204675912064
  • NII Article ID
    130003874394
  • DOI
    10.4009/jsdt1985.25.881
  • ISSN
    18846211
    09115889
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top